Vol. 21 No. 1 (2020)

Vol. 21 No. 1 (2020)

Published: 2020-02-06

Funding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy

Massimiliano Povero, Lorenzo Pradelli
- HTML
- PDF
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region

Monica Bocchia, Alberto Bosi, Enrico Capochiani, Stefania Ciolli, Romano Danesi, Sara Galimberti, Alessandro Gozzetti, Sabrina Moretti, Ubaldo Occhini, Mario Petrini
- HTML
- PDF
Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa

Matteo Nicola Dario Di Minno, Lucia D'Angiolella, Paolo Angelo Cortesi, Angelo Claudio Molinari, Lorenzo Giovanni Mantovani
- HTML
- PDF
The Economic Burden of Different Multiple Sclerosis Courses: Analysis from Italian Administrative and Clinical Databases

Paolo Angelo Cortesi, Paolo Cozzolino, Ruggero Capra, Giancarlo Cesana, Lorenzo Giovanni Mantovani
- HTML
Clinical Impact of two Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Giovanni Gancitano, Roberto Ravasio, Lorenzo Cattelino, Paolo Di Procolo, Diego Cortinovis
- HTML
- PDF
Analysis of Market Access Agreements in Turkey

Guvenc Kockaya, Okan Atalay, Mustafa Kurnaz, Selin Okcun, Nazlı Sencan, Cigdem Gedik, Mete Saylan, Gulpembe Oguzhan
- HTML
- PDF

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective

Daniela Paola Roggeri, Ezio Zanon, Chiara Biasoli, Alessandro Roggeri
- HTML
- PDF